These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37545264)

  • 1. The risk factors for coagulation disorder of chimeric antigen receptor-T cell therapy in patients with hematological tumors: A systematic review and meta-analysis.
    Xia Y; Tang L; Hu Y
    Technol Health Care; 2023; 31(6):2363-2380. PubMed ID: 37545264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
    Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
    BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The characteristics and impact on prognosis of cytopenia after anti-BCMA-CAR-T therapy in patients with relapsed and refractory multiple myeloma].
    Shen XX; Yao Y; Xia Y; Jin YY; Zhang R; Li JY; Chen LJ
    Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):507-513. PubMed ID: 38317362
    [No Abstract]   [Full Text] [Related]  

  • 4. Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
    Zhang L; Shen X; Yu W; Li J; Zhang J; Zhang R; Li J; Chen L
    Ann Med; 2021 Dec; 53(1):1547-1559. PubMed ID: 34459681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venous Thromboembolism Risk in Hematological Malignancies Post-Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Meta-Analysis of Phase 2 and Phase 3 Clinical Trials.
    Chitkara A; Sreenivasan S; Yin Y; Rai M; Sadashiv S
    Curr Oncol; 2024 Jul; 31(8):4338-4345. PubMed ID: 39195306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive analysis of coagulopathy during anti-B cell maturation antigen chimeric antigen receptor-T therapy in multiple myeloma, a retrospective study based on LEGEND-2.
    Liu R; Lv Y; Hong F; Zhao W; Lei B; Liu J; Zhang W; He A; Wang F
    Hematol Oncol; 2023 Oct; 41(4):704-717. PubMed ID: 37186314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma.
    Li H; Zhao L; Sun Z; Yao Y; Li L; Wang J; Hua T; Ji S; Wang S; Cheng H; Shi M; Li Z; Zeng L; Wu Q; Qiao J; Chen C; Zheng J; Cao J; Xu K
    Front Immunol; 2022; 13():1019548. PubMed ID: 36330523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy.
    Zhang Q; Zu C; Meng Y; Lyu Y; Hu Y; Huang H
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):144-150. PubMed ID: 36161293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.
    Zhao WH; Liu J; Wang BY; Chen YX; Cao XM; Yang Y; Zhang YL; Wang FX; Zhang PY; Lei B; Gu LF; Wang JL; Yang N; Zhang R; Zhang H; Shen Y; Bai J; Xu Y; Wang XG; Zhang RL; Wei LL; Li ZF; Li ZZ; Geng Y; He Q; Zhuang QC; Fan XH; He AL; Zhang WG
    J Hematol Oncol; 2018 Dec; 11(1):141. PubMed ID: 30572922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features of hemophagocytic syndrome following BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.
    Zu C; Wang K; Zhang Q; Hu Y; Huang H
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):160-166. PubMed ID: 36161295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors of acute kidney injury during BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.
    Lyu Y; Zhang M; Wei G; Ding S; Hu Y; Huang H
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):137-143. PubMed ID: 36161296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
    Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K
    Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma.
    Zhang Q; Zu C; Jing R; Feng Y; Zhang Y; Zhang M; Lv Y; Cui J; Zhou L; Meng Y; Wang L; Cen Z; Chang AH; Hu Y; Huang H
    Front Immunol; 2023; 14():1125357. PubMed ID: 37215107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.
    Roex G; Timmers M; Wouters K; Campillo-Davo D; Flumens D; Schroyens W; Chu Y; Berneman ZN; Lion E; Luo F; Anguille S
    J Hematol Oncol; 2020 Dec; 13(1):164. PubMed ID: 33272302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma.
    Reyes KR; Huang CY; Lo M; Arora S; Chung A; Wong SW; Wolf J; Olin RL; Martin T; Shah N; Banerjee R
    Transplant Cell Ther; 2023 Jun; 29(6):350-355. PubMed ID: 36933659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
    Raje N; Berdeja J; Lin Y; Siegel D; Jagannath S; Madduri D; Liedtke M; Rosenblatt J; Maus MV; Turka A; Lam LP; Morgan RA; Friedman K; Massaro M; Wang J; Russotti G; Yang Z; Campbell T; Hege K; Petrocca F; Quigley MT; Munshi N; Kochenderfer JN
    N Engl J Med; 2019 May; 380(18):1726-1737. PubMed ID: 31042825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy.
    Davis JA; Sborov DW; Wesson W; Julian K; Abdallah AO; McGuirk JP; Ahmed N; Hashmi H
    Transplant Cell Ther; 2023 Sep; 29(9):567-571. PubMed ID: 37225044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
    Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
    Front Immunol; 2021; 12():755866. PubMed ID: 34777368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.